Bladder Cancer

BLC Journal | Dedicated to expediting our understanding & improving treatments of bladder and upper urinary tract cancers | Editors Seth Lerner, Dan Theodorescu

[Bladder Cancer @BladderCaJrnl]

Stay updated with the latest content from our #BladderCancer journal by signing up to get news direct to your inbox. Go to: https://t.co/TATcPpm0Wu

Keep informed about new articles, challenging cases, reviews, & other features like our Clinical Trials Corner! #GoldOpenAccess

[Bladder Cancer @BladderCaJrnl]

RESEARCH REPORT: BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis by Zine-Eddine KHENE et al. https://t.co/neFIrDOK9O @FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

SHORT COMMUNICATION: Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies by Yelba Castellon-Lopez and Patricia Thompson. https://t.co/5jZpnrfy7E @FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

The First Systematic Review and Meta-Analysis of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors in Urothelial Cancer: Efficacy, Clinical Use and Future Applications by @mjmoussa_ et al. https://t.co/1wn7WfV42x @FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

REVIEW: Systemic induction therapy in patients with locally advanced or node-positive urothelial
carcinoma: evaluating treatment outcomes by Vera Rutten et al. https://t.co/aY1O1PxKLa @FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Enrique Grande @drenriquegrande]

⚡️ On @EUplatinum - Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure.

- Feasible administration with negligible toxicity.
- Encouraging efficacy as a localized immune checkpoint inhibitor.
- Intravesical delivery may surpass systemic approaches.

#BladderCancer #Immunotherapy @OncoAlert

https://t.co/mYNfuU9HO6

[Mohammad Jad Moussa, MD, MSc @mjmoussa_]

🔥NOW in @BladderCaJrnl of @BladderCancerUS👉Can Combining ICIs w/ Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer? @OAlhalabiMD @MDAndersonNews

1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed. Better patient selection🔑?

[Bladder Cancer @BladderCaJrnl]

RESEARCH REPORT: North American Study and Meta-analysis Evaluating Performance of Bladder EpiCheck®, a FDA cleared test, in Non-Muscle Invasive Bladder Cancer Recurrence by Neil Fleshner et al. https://t.co/2Uv2XG6QnW @FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

Research Report: Repeat TURBT in large volume HG Ta NMIBC treated with induction BCG therapy was not associated with improved high-risk recurrence-free survival. @durant_adri et al. https://t.co/ORKZHO0owb.
@FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

RESEARCH REPORT: Effectiveness of prolonged antibiotic prophylaxis in radical cystectomy: preliminary analysis of the MACS randomized clinical trial by Mariya Berkut et al. https://t.co/kmnP9u9r29.
@FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

SHORT COMMUNICATION: Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists by Ivy Beeren et al. https://t.co/rLZ4ZTPgaR
@FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

POSITION PAPER: Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer by @RonaldChenMD, @slernerbcmedu1, @sonpavde, @HimanshuNagarMD, @Parminder1699 et al. https://t.co/uhAqowVeyG
@FaltasLab @Dan_Theodorescu

[Bladder Cancer @BladderCaJrnl]

NEW REVIEW focusing on ctDNA👉Perioperative use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now👈by @DrTylerStewart et al. https://t.co/YXYflyBQrv
@DrChoueiri @FaltasLab @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

New Research Report: A molecular urine assay to detect recurrences during surveillance of high-risk non-muscle invasive bladder cancer by @FCdeJong, @JoepJdeJong, et al. https://t.co/x8M60X3WOm
@FaltasLab @Dan_Theodorescu @slernerbcmedu1

[Bladder Cancer @BladderCaJrnl]

Happy to present the latest review in Bladder Cancer by @SandeepGurramMD and @RathiNityam from @NCICCR_UroOnc "Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer" discussing
✅Rationale for devices
✅Devices available
✅Mechanisms
✅Efficacy
✅Safety
✅Future Studies

[Enrique Grande @drenriquegrande]

⚡️ Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial

#BladderCancer @docpriyamvada
@VedangMurthy

https://t.co/TH3iXkFCdK

[Bladder Cancer Advocacy Network @BladderCancerUS]

In @Nature: Full text article "Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer." Click here to read it: https://t.co/ibFuHa5lAJ

[Bladder Cancer @BladderCaJrnl]

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. 👇

[Dr. Bishoy M. Faltas @FaltasLab]

🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! https://t.co/sU6uF9rNvI

[Enrique Grande @drenriquegrande]

⚡️ On @EUplatinum - Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma

#BladderCancer @IverNordentoft
@SiaLindskrog

https://t.co/FeM9s8YDHb

[Enrique Grande @drenriquegrande]

⚡️ Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy

#BladderCancer @mjmoussa_
@OAlhalabiMD @PavlosMsaouel
⁩ @DocMattCampbell

https://t.co/EhwyBArPH8
⁩ ⁦

[Roger Li @UrogerliMD]

Out now @EUplatinum - our review of FGFR inhibition in #bladdercancer covering:

👉MoA of receptor mediated signaling
👉Incidence in UC
👉Impact on TiME
👉Clinical trials and results
👉Possible mech of resistance

Prelude to #PrecisionMedicine in UC

https://t.co/G5iK0HGsTw